Drugs / Octaplas LG
Octaplas LG
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01063595 | Dec 2009 → Jul 2010 | — | Octapharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07035509 | Jul 2025 → Jul 2026 overdue | infectious disease with sepsis | Fundación Cardioinfantil Instituto de Cardiología | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT01938378 | Apr 2015 → Jan 2019 | — | Octapharma | Completed | No outcome recorded |
| Phase 4 | NCT02050841 | Dec 2014 → Dec 2017 | blood coagulation disease, liver disorder | Octapharma | Completed | No outcome recorded |
| Phase 4 | NCT01754545 | Sep → Nov 2012 | congenital thrombotic thrombocytopenic purpura | St. Olavs Hospital | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04580563 | Oct 2020 → Dec 2022 | disseminated intravascular coagulation, infectious disease with sepsis | University Hospital, Strasbourg, France | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03092245 Comparator | Apr 2017 → Apr 2019 | infectious disease with sepsis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06934278 Comparator | May 2025 → Dec 2030 expected | adolescent idiopathic scoliosis | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02875236 Comparator | Sep → Nov 2016 | infectious disease with sepsis | Rigshospitalet, Denmark | Terminated | No outcome recorded |
| Phase 4 | NCT02253082 Comparator | Nov 2014 → Sep 2016 | thoracic aortic aneurysm | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01910675 Comparator | Jul 2013 → Oct 2018 | — | Helsinki University Central Hospital | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octaplas LG | “Octaplas LG is a medication approved for use in Colombia.” NCT07035509 ↗ |
| Known as | Octaplas | “Objective To compare pooled human plasma (PHP, OCTAPLAS) vs. crystalloid (PLASMALYTE, comparator) for intraoperative bleeding, drain output, and hidden blood loss” NCT06934278 ↗5“Twenty patients in the FFP group receive 4 units of FFP (Octaplas).” NCT01910675 ↗ “Pooled human plasma (Octaplas, 10 mL/kg, max 400 mL)” NCT06934278 ↗ |
| Known as | Pharmaceutical fresh frozen plasma | “Pharmaceutical fresh frozen plasma (OCTAPLAS LG®), bolus dose of 10 mL/kg (max. 500 mL) administered over \<15 minutes” NCT07035509 ↗ |
| Known as | PHP | “Objective To compare pooled human plasma (PHP, OCTAPLAS) vs. crystalloid (PLASMALYTE, comparator)” NCT06934278 ↗ |
| Known as | pooled human plasma | “Pooled human plasma (Octaplas, 10 mL/kg, max 400 mL)” NCT06934278 ↗ |
| Action | Restore | “replacement of single or multiple coagulation factors” PMID 33042916 ↗ Sep 2020 |
| Modality | Other / unclassified | “Octaplas LG was composed of human coagulation-active plasma” NCT01063595 ↗ |
| Route | Intravenous | “Participants received 1200 mL of Octaplas LG intravenously once.” NCT01063595 ↗ |